schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals."
.: "arise: a phase 3 randomized trial of erenumab for episodic migraine."
.
.
the data also revealed 66% of trusts who replied had at least one cancer patient forced to wait over six months to start treatment, and 69% had a worse longest wait than in 2010.
.
.